BARBARA ANN KARMANOS CANCER INSTITUTE

The organization over time

Each line starts at 100 in 2017, so what you read is the shape rather than the size: 150 means half as much again as 2017, 50 means half. The number beside each label in the key is where it ended. The shaded band is where the middle 50% of its peers' revenue would sit, given their growth.

How it's funded, over time

Each bar is one year's revenue split into where it came from, and every bar is the same height — these are shares, not amounts, so a year that raised twice as much looks the same size. Hover a bar for the split.

Surplus & reserves

Operating surplus or deficit each year, and months of liquidity in hand. 6 of the last 8 reported years ran a deficit.

Who funds it, year by year

2017 → 2023: the base broadened from 24 funders to 25 funders, grant income rose $435k → $1.1M.

10 of 64 of your funders are donor-advised or pass-through sponsors (tagged DAF) — 8% of grant dollars received. That money is really individual donors directing a sponsor; the institutions to cultivate are the non-DAF funders.

Left out of every figure on this page: $30M from 9 payers (the payer shares this organization's board, largest McLaren Health Care Corporation). These are real filings, and they are not money BARBARA ANN KARMANOS CANCER INSTITUTE raised.

From the IRS filings of BARBARA ANN KARMANOS CANCER INSTITUTE’s funders (the co-funder graph). Top 30 of 64 funders by total. Association, not causation. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

How concentrated its funding is

BARBARA ANN KARMANOS CANCER INSTITUTE leans on a few funders — its largest provides 37% of grant income and the top three 60%; half comes from just 2 funders.

42% of the income these shares are computed over arrives through pass-through sponsors or from payers whose filings do not say what kind of payment it is. Concentration is still measured over all of it, because the money is real; what it does not support is a claim about how many institutions have chosen to fund BARBARA ANN KARMANOS CANCER INSTITUTE.

Largest funder’s share by year: 2017 49% · 2018 49% · 2019 38% · 2020 52% · 2021 19% · 2022 59% · 2023 50% — broadly stable.

“Effective funders” = inverse Herfindahl index (1 / Σ shareᵢ²) — the number of equal-sized funders that would give the same concentration. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.

How long its funders stay

33% of BARBARA ANN KARMANOS CANCER INSTITUTE's funders are still giving 3 years after their first grant; 59% give in more than one year at all.

Share of funders still giving k years after their first recorded grant, pooled across every acquisition cohort. A funder counts as retained in a year only if it made a grant that year. Measured to FY2023, the last fiscal year that has finished arriving — a funder cannot be counted as lapsed in a year most filers have not reached.

Where its funders are

87% of BARBARA ANN KARMANOS CANCER INSTITUTE's grant income comes from Michigan funders.

Funder states come from each funder’s own filing. $500k arriving through sponsors registered in 10 statesis excluded from the map and the split above: a sponsor holds money on a donor’s behalf, so its registered address would place those dollars somewhere no donor need ever have been. Trends are read to FY2023, the last fiscal year that has finished arriving. FY2024–FY2026 are still being filed and are shown unshaded; they do not move any figure on this page.